YQ128 is a potent and selective second-generation NLRP3 inflammasome inhibitor (IC50 = 0.30 µM); it significantly and selectively inhibits IL-1β production without affecting TNF-α production; it exhibits anti-inflammatory activity; it can cross the blood-brain barrier to reach the central nervous system; it suppresses IL-1β release from peritoneal macrophages in response to LPS/ATP challenge (IC50 = 1.59 µM); it shows no significant toxicity in hCMEC/D3 cells at 20 µM for 2 hours; it demonstrates in vivo efficacy by triggering IL-1β production in an NLRP3-dependent manner in C57BL/6 mice at 10 mg/kg.